Eintrag weiter verarbeiten
Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets.
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , , , |
| In: | Journal of Clinical Oncology, 31, 2013, 15_suppl, S. e15071-e15071 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Heetfeld, Maximilian Kasajima, Atsuko Koch, Arend Milone, Francesco Steffen, Ingo Dietel, Manfred Sasano, Hironobu Wiedenmann, Bertram Pavel, Marianne E. Heetfeld, Maximilian Kasajima, Atsuko Koch, Arend Milone, Francesco Steffen, Ingo Dietel, Manfred Sasano, Hironobu Wiedenmann, Bertram Pavel, Marianne E. |
|---|---|
| author |
Heetfeld, Maximilian Kasajima, Atsuko Koch, Arend Milone, Francesco Steffen, Ingo Dietel, Manfred Sasano, Hironobu Wiedenmann, Bertram Pavel, Marianne E. |
| spellingShingle |
Heetfeld, Maximilian Kasajima, Atsuko Koch, Arend Milone, Francesco Steffen, Ingo Dietel, Manfred Sasano, Hironobu Wiedenmann, Bertram Pavel, Marianne E. Journal of Clinical Oncology Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets. Cancer Research Oncology |
| author_sort |
heetfeld, maximilian |
| spelling |
Heetfeld, Maximilian Kasajima, Atsuko Koch, Arend Milone, Francesco Steffen, Ingo Dietel, Manfred Sasano, Hironobu Wiedenmann, Bertram Pavel, Marianne E. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e15071 <jats:p> e15071 </jats:p><jats:p> Background: Poorly differentiated neuroendocrine carcinomas (NEC G3) represent a subgroup of neuroendocrine neoplasms with aggressive clinical behavior and poor prognosis, but showing quite variable clinical courses. In metastatic disease objective response to first-line therapy with cisplatin/ etoposide ranges between 40-67%, however median duration of response is short (4 to 9 months). There is no established second-line therapy. Methods: Clinical data of 42 patients with gastro-entero-pancreatic NEC G3 were analyzed in retrospect. In 26 cases tissue was analyzed for cell size, expression of p-mTOR and downstream effectors (p-eIF4E and p-4EBP1), somatostatin receptor (SSTR)-subtypes and growth factor receptors (EGFR and IGF-1R). Histopathological findings were analyzed using Kaplan-Meier curve, log rank test and Cox regression. Results: Patients with large cell NEC showed a more favorable survival than patients with small cell NEC. Median overall survival (mOS) was 31 versus 11 months (P=0.034). Expression of p-mTOR and p-eIF4E was seen in 64% and 24% of cases. High expression levels of p-mTOR (mOS 9 vs 25 months, P=0.026) and expression of p-eIF4E (mOS 9 vs 25 months, P=0.015) was significantly associated with shorter survival. In multivariate Cox regression p-mTOR and p-eIF4E proved to be independent prognostic factors for survival taking cell size and TNM staging into account. EGFR (cytoplasmatic and nuclear) and IGF-1R expression was found in 73.1%, 65.4% and 69.2% of the cases respectively, without significant association to survival. Expression of SSTR subtypes, Ki67 value and response to first line chemotherapy was not of prognostic value analyzed by log rank test. Conclusions: The clinical impact of cell size discrimination requires further evaluation in NEC G3. The mTOR pathway seems to play a role in tumor growth in some NEC and may represent a novel therapeutic target. </jats:p> Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets. Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2013.31.15_suppl.e15071 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMy4zMS4xNV9zdXBwbC5lMTUwNzE |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMy4zMS4xNV9zdXBwbC5lMTUwNzE |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Society of Clinical Oncology (ASCO), 2013 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2013 |
| issn |
1527-7755 0732-183X |
| issn_str_mv |
1527-7755 0732-183X |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
heetfeld2013poorlydifferentiatedneuroendocrinecarcinomanecg3prognosticfactorsandpotentialnoveltargets |
| publishDateSort |
2013 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets. |
| title_unstemmed |
Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets. |
| title_full |
Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets. |
| title_fullStr |
Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets. |
| title_full_unstemmed |
Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets. |
| title_short |
Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets. |
| title_sort |
poorly differentiated neuroendocrine carcinoma (nec g3): prognostic factors and potential novel targets. |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e15071 |
| publishDate |
2013 |
| physical |
e15071-e15071 |
| description |
<jats:p> e15071 </jats:p><jats:p> Background: Poorly differentiated neuroendocrine carcinomas (NEC G3) represent a subgroup of neuroendocrine neoplasms with aggressive clinical behavior and poor prognosis, but showing quite variable clinical courses. In metastatic disease objective response to first-line therapy with cisplatin/ etoposide ranges between 40-67%, however median duration of response is short (4 to 9 months). There is no established second-line therapy. Methods: Clinical data of 42 patients with gastro-entero-pancreatic NEC G3 were analyzed in retrospect. In 26 cases tissue was analyzed for cell size, expression of p-mTOR and downstream effectors (p-eIF4E and p-4EBP1), somatostatin receptor (SSTR)-subtypes and growth factor receptors (EGFR and IGF-1R). Histopathological findings were analyzed using Kaplan-Meier curve, log rank test and Cox regression. Results: Patients with large cell NEC showed a more favorable survival than patients with small cell NEC. Median overall survival (mOS) was 31 versus 11 months (P=0.034). Expression of p-mTOR and p-eIF4E was seen in 64% and 24% of cases. High expression levels of p-mTOR (mOS 9 vs 25 months, P=0.026) and expression of p-eIF4E (mOS 9 vs 25 months, P=0.015) was significantly associated with shorter survival. In multivariate Cox regression p-mTOR and p-eIF4E proved to be independent prognostic factors for survival taking cell size and TNM staging into account. EGFR (cytoplasmatic and nuclear) and IGF-1R expression was found in 73.1%, 65.4% and 69.2% of the cases respectively, without significant association to survival. Expression of SSTR subtypes, Ki67 value and response to first line chemotherapy was not of prognostic value analyzed by log rank test. Conclusions: The clinical impact of cell size discrimination requires further evaluation in NEC G3. The mTOR pathway seems to play a role in tumor growth in some NEC and may represent a novel therapeutic target. </jats:p> |
| container_issue |
15_suppl |
| container_start_page |
0 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
31 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792329801466380292 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T13:14:54.78Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Poorly+differentiated+neuroendocrine+carcinoma+%28NEC+G3%29%3A+Prognostic+factors+and+potential+novel+targets.&rft.date=2013-05-20&genre=article&issn=1527-7755&volume=31&issue=15_suppl&pages=e15071-e15071&jtitle=Journal+of+Clinical+Oncology&atitle=Poorly+differentiated+neuroendocrine+carcinoma+%28NEC+G3%29%3A+Prognostic+factors+and+potential+novel+targets.&aulast=Pavel&aufirst=Marianne+E.&rft_id=info%3Adoi%2F10.1200%2Fjco.2013.31.15_suppl.e15071&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792329801466380292 |
| author | Heetfeld, Maximilian, Kasajima, Atsuko, Koch, Arend, Milone, Francesco, Steffen, Ingo, Dietel, Manfred, Sasano, Hironobu, Wiedenmann, Bertram, Pavel, Marianne E. |
| author_facet | Heetfeld, Maximilian, Kasajima, Atsuko, Koch, Arend, Milone, Francesco, Steffen, Ingo, Dietel, Manfred, Sasano, Hironobu, Wiedenmann, Bertram, Pavel, Marianne E., Heetfeld, Maximilian, Kasajima, Atsuko, Koch, Arend, Milone, Francesco, Steffen, Ingo, Dietel, Manfred, Sasano, Hironobu, Wiedenmann, Bertram, Pavel, Marianne E. |
| author_sort | heetfeld, maximilian |
| container_issue | 15_suppl |
| container_start_page | 0 |
| container_title | Journal of Clinical Oncology |
| container_volume | 31 |
| description | <jats:p> e15071 </jats:p><jats:p> Background: Poorly differentiated neuroendocrine carcinomas (NEC G3) represent a subgroup of neuroendocrine neoplasms with aggressive clinical behavior and poor prognosis, but showing quite variable clinical courses. In metastatic disease objective response to first-line therapy with cisplatin/ etoposide ranges between 40-67%, however median duration of response is short (4 to 9 months). There is no established second-line therapy. Methods: Clinical data of 42 patients with gastro-entero-pancreatic NEC G3 were analyzed in retrospect. In 26 cases tissue was analyzed for cell size, expression of p-mTOR and downstream effectors (p-eIF4E and p-4EBP1), somatostatin receptor (SSTR)-subtypes and growth factor receptors (EGFR and IGF-1R). Histopathological findings were analyzed using Kaplan-Meier curve, log rank test and Cox regression. Results: Patients with large cell NEC showed a more favorable survival than patients with small cell NEC. Median overall survival (mOS) was 31 versus 11 months (P=0.034). Expression of p-mTOR and p-eIF4E was seen in 64% and 24% of cases. High expression levels of p-mTOR (mOS 9 vs 25 months, P=0.026) and expression of p-eIF4E (mOS 9 vs 25 months, P=0.015) was significantly associated with shorter survival. In multivariate Cox regression p-mTOR and p-eIF4E proved to be independent prognostic factors for survival taking cell size and TNM staging into account. EGFR (cytoplasmatic and nuclear) and IGF-1R expression was found in 73.1%, 65.4% and 69.2% of the cases respectively, without significant association to survival. Expression of SSTR subtypes, Ki67 value and response to first line chemotherapy was not of prognostic value analyzed by log rank test. Conclusions: The clinical impact of cell size discrimination requires further evaluation in NEC G3. The mTOR pathway seems to play a role in tumor growth in some NEC and may represent a novel therapeutic target. </jats:p> |
| doi_str_mv | 10.1200/jco.2013.31.15_suppl.e15071 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMy4zMS4xNV9zdXBwbC5lMTUwNzE |
| imprint | American Society of Clinical Oncology (ASCO), 2013 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2013 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1527-7755, 0732-183X |
| issn_str_mv | 1527-7755, 0732-183X |
| language | English |
| last_indexed | 2024-03-01T13:14:54.78Z |
| match_str | heetfeld2013poorlydifferentiatedneuroendocrinecarcinomanecg3prognosticfactorsandpotentialnoveltargets |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | e15071-e15071 |
| publishDate | 2013 |
| publishDateSort | 2013 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Heetfeld, Maximilian Kasajima, Atsuko Koch, Arend Milone, Francesco Steffen, Ingo Dietel, Manfred Sasano, Hironobu Wiedenmann, Bertram Pavel, Marianne E. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e15071 <jats:p> e15071 </jats:p><jats:p> Background: Poorly differentiated neuroendocrine carcinomas (NEC G3) represent a subgroup of neuroendocrine neoplasms with aggressive clinical behavior and poor prognosis, but showing quite variable clinical courses. In metastatic disease objective response to first-line therapy with cisplatin/ etoposide ranges between 40-67%, however median duration of response is short (4 to 9 months). There is no established second-line therapy. Methods: Clinical data of 42 patients with gastro-entero-pancreatic NEC G3 were analyzed in retrospect. In 26 cases tissue was analyzed for cell size, expression of p-mTOR and downstream effectors (p-eIF4E and p-4EBP1), somatostatin receptor (SSTR)-subtypes and growth factor receptors (EGFR and IGF-1R). Histopathological findings were analyzed using Kaplan-Meier curve, log rank test and Cox regression. Results: Patients with large cell NEC showed a more favorable survival than patients with small cell NEC. Median overall survival (mOS) was 31 versus 11 months (P=0.034). Expression of p-mTOR and p-eIF4E was seen in 64% and 24% of cases. High expression levels of p-mTOR (mOS 9 vs 25 months, P=0.026) and expression of p-eIF4E (mOS 9 vs 25 months, P=0.015) was significantly associated with shorter survival. In multivariate Cox regression p-mTOR and p-eIF4E proved to be independent prognostic factors for survival taking cell size and TNM staging into account. EGFR (cytoplasmatic and nuclear) and IGF-1R expression was found in 73.1%, 65.4% and 69.2% of the cases respectively, without significant association to survival. Expression of SSTR subtypes, Ki67 value and response to first line chemotherapy was not of prognostic value analyzed by log rank test. Conclusions: The clinical impact of cell size discrimination requires further evaluation in NEC G3. The mTOR pathway seems to play a role in tumor growth in some NEC and may represent a novel therapeutic target. </jats:p> Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets. Journal of Clinical Oncology |
| spellingShingle | Heetfeld, Maximilian, Kasajima, Atsuko, Koch, Arend, Milone, Francesco, Steffen, Ingo, Dietel, Manfred, Sasano, Hironobu, Wiedenmann, Bertram, Pavel, Marianne E., Journal of Clinical Oncology, Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets., Cancer Research, Oncology |
| title | Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets. |
| title_full | Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets. |
| title_fullStr | Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets. |
| title_full_unstemmed | Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets. |
| title_short | Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets. |
| title_sort | poorly differentiated neuroendocrine carcinoma (nec g3): prognostic factors and potential novel targets. |
| title_unstemmed | Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets. |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e15071 |